Despite its distinct clinical presentation, IGH::IL3‐rearranged leukemia poses numerous diagnostic challenges, primarily due to the low percentage of blasts in the bone marrow and the necessity to exclude much more common reactive hypereosinophilic syndromes. This evidence concerns the gene IL3 and leukemia.